Alterity Therapeutics Limited ATHE
Set alert
2.16 USD -0.07 -3.29%
At close · Oct 30
2.12 -0.04 -1.85%
After hours · Oct 30, 4:00 PM ET
2.11 Day range 2.12
2.01 52-week range 5.89
- YTD
- -29.87%
- 1 year
- -53.04%
- Open
- 2.12
- Prev close
- 2.23
- Mkt cap
- 41.24M
- Vol
- 8.89K
- Avg vol
- 20.46K
- EPS
- -0.90
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.11
- High
- 2.12
- Forward P/E
- -27.22
- Beta
- 0.68
- Short ratio
- 0.04
- Inst. own
- 1.28%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.48
- 200-d avg
- 1.67
- 1y target
- 8.00
1Y chart
Signals (57)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 2026 | 2 days ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| RSI: Oversold | Sep 15, 2026 | 1 month ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 31, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Aug 12, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 11, 2026 | 2 months ago |
| SMA: Bearish | Jul 28, 2026 | 3 months ago |
| SMA: Bullish | Jul 27, 2026 | 3 months ago |
| SMA: Bearish | Jul 24, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| RSI: Overbought | Jul 6, 2026 | 3 months ago |
| RSI: Overbought | Jul 1, 2026 | 4 months ago |
| RSI: Overbought | Jun 17, 2026 | 4 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 10, 2026 | 4 months ago |
| SMA: Bullish | Jun 9, 2026 | 4 months ago |
| SMA: Bullish | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | Jun 4, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 29, 2026 | 5 months ago |
| SMA: Bearish | May 27, 2026 | 5 months ago |
| MACD: Sell Signal | May 5, 2026 | 6 months ago |
| SMA: Bullish | Apr 17, 2026 | 6 months ago |
| RSI: Overbought | Apr 17, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 1, 2026 | 7 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| SMA: Bearish | Mar 26, 2026 | 7 months ago |
| SMA: Bullish | Mar 25, 2026 | 7 months ago |
| SMA: Bearish | Mar 20, 2026 | 7 months ago |
| SMA: Bullish | Mar 18, 2026 | 7 months ago |
| SMA: Bearish | Mar 17, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 17, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 5, 2026 | 8 months ago |
| MACD: Sell Signal | Mar 4, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 26, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 20, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 9, 2026 | 8 months ago |
| SMA: Bullish | Feb 6, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 30, 2026 | 9 months ago |
| SMA: Bearish | Jan 29, 2026 | 9 months ago |
| SMA: Bullish | Jan 23, 2026 | 9 months ago |
| SMA: Bearish | Jan 20, 2026 | 9 months ago |
| SMA: Bullish | Jan 16, 2026 | 9 months ago |
| SMA: Bearish | Jan 13, 2026 | 9 months ago |
| SMA: Bullish | Jan 9, 2026 | 9 months ago |
| MACD: Buy Signal | Dec 22, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 15, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 3, 2025 | 11 months ago |
| MACD: Sell Signal | Dec 2, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 26, 2025 | 11 months ago |
| SMA: Bearish | Oct 31, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 31, 2025 | 1 year ago |
Key statistics
- Market cap
- 21.42M
- Enterprise value
- 11.69B
- Trailing P/E
- 0.00
- Forward P/E
- -27.22
- PEG ratio
- 0.00
- Price / sales
- 5.33
- Price / book
- 816.67
- EPS (TTM)
- -4.21
- Beta
- 0.68
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 4.02M
- Revenue growth
- 38.40%
- Free cash flow
- -5.36M
- Total cash
- 12.64M
- Total debt
- 159.04K
- Return on equity
- -104.47%
- Shares outstanding
- 8.74M
- Short % of float
- 0.02%
- 50-day average
- 1.48
- 200-day average
- 1.67
Analyst view
Consensus: buy
Buy
Price target (mean) 8.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
ATHE Revenue — annual 3.61M
ATHE Net income — annual -23.40M
ATHE EPS — annual -1.33
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 12, 2024 | Maxim Group | init | — | Buy |
| Mar 7, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Jun 5, 2023 | Ladenburg Thalmann | main | Buy | Buy |
About Alterity Therapeutics Limited
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Website
- alteritytherapeutics.com
News
- Alterity Therapeutics Releases Appendix 4C – Q1 FY27 Quarterly Cash Flow Report & Corporate Update
- Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference
- Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson's Disease and Movement Disorders
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Stock Has Average Price Target of $10.00
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Lake Street Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $10
- Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
- Alterity Therapeutics Secures Key US Patent for Lead Asset
- Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
Your note
Sign in to keep a note on ATHE — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Morgan Stanley | 0.50% | 44,501 | 109.03K | Sep 29, 2024 |
| HB Wealth Management, LLC | 0.27% | 23,783 | 58.27K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.16% | 13,932 | 34.13K | Sep 29, 2024 |
| UBS Group AG | 0.14% | 12,685 | 31.08K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.13% | 11,488 | 28.14K | Sep 29, 2024 |
| Twin Lakes Capital Management, LLC | 0.07% | 5,925 | 14.52K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.01% | 1,155 | 2.83K | Oct 30, 2024 |